Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
US9918972B2 · kind B2 · utility
0Cited by
1References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 23, 2015 |
| Grant date | Mar 20, 2018 |
| Priority date | — |
| Expiry date | Dec 23, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and ART-838. The second agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.